Knights of Columbus Asset Advisors LLC Acquires New Holdings in Xeris Biopharma Holdings, Inc. $XERS

Knights of Columbus Asset Advisors LLC bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 133,378 shares of the company’s stock, valued at approximately $1,275,000. Knights of Columbus Asset Advisors LLC owned approximately 0.07% of Xeris Biopharma as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV purchased a new position in Xeris Biopharma during the first quarter worth $27,000. GK Wealth Management LLC purchased a new stake in shares of Xeris Biopharma in the third quarter valued at $32,000. Allworth Financial LP purchased a new stake in shares of Xeris Biopharma in the second quarter valued at $34,000. State of Wyoming acquired a new stake in shares of Xeris Biopharma during the second quarter valued at $52,000. Finally, William Mack & Associates Inc. acquired a new stake in shares of Xeris Biopharma during the third quarter valued at $53,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on XERS. Piper Sandler reiterated a “neutral” rating and set a $12.00 price objective (up from $8.00) on shares of Xeris Biopharma in a research report on Friday, November 6th. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. Oppenheimer reaffirmed an “outperform” rating and set a $21.00 price target (up from $18.00) on shares of Xeris Biopharma in a research note on Friday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, November 4th. Finally, Leerink Partners lifted their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the completion of the sale, the insider directly owned 1,086,130 shares in the company, valued at approximately $11,111,109.90. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total transaction of $312,250.00. Following the transaction, the insider directly owned 1,559,208 shares of the company’s stock, valued at $19,474,507.92. This trade represents a 1.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 168,332 shares of company stock worth $1,678,971 in the last three months. Company insiders own 4.35% of the company’s stock.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $16.65 on Friday. The company has a market cap of $3.04 billion, a P/E ratio of -332.93 and a beta of 0.61. The business has a fifty day simple moving average of $10.24 and a 200-day simple moving average of $7.79. Xeris Biopharma Holdings, Inc. has a 52 week low of $5.25 and a 52 week high of $16.88. The company has a quick ratio of 1.02, a current ratio of 2.15 and a debt-to-equity ratio of 3.89.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a positive return on equity of 147.75% and a negative net margin of 1.76%. Equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.15 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.